Royalty Report: Drugs, Genome, Drug Discovery – Collection: 289233

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Genome
  • Drug Discovery
  • Diagnostic
  • Antibody
  • Therapeutic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 289233

License Grant
The University grants, in the territory
– an exclusive commercial license to Universitys ownership. interest under patent rights, and
– a license to use biological materials to make and have made, to use and have used, to sell and have sold the Licensed Products, and to practice the Licensed Processes.
License Property
The intellectual property is for signalin homologs, bioactive fragments thereof, diagnostic methods involving the signalin genes and/or gene products and drug screening protocols involving signalin genes and/or gene products,

The patent is for Signalin Family of TGFO Signal Transduction Proteins and Uses Related Thereto.

Field of Use
The field of use is as a diagnostic or therapeutic in any field.

IPSCIO Record ID: 203513

License Grant
The University grants a worldwide license, under the patent rights to make and have made, to use and have used, to sell and have sold the Products for the life of the patent rights, and a worldwide license to use Biological Materials to make and have made, to use and have used, to sell and have sold or to identify the Milestone Products. Such license shall include the right to grant sublicenses. Licensor grants the right to assign the licenses granted or to be granted.  This agreement has an exclusive period.
License Property
The Licensed products shall mean products, the manufacture, use or sale of which would, absent the license granted hereunder, infringe a Claim, with the exception of any antibodies which bind to a hedgehog protein which shall be designated as Milestone Products.

Biological Materials shall mean the proprietary materials developed in the laboratories of certain Drs. as a result of research concerning the licensed subject matter, identified including Polypepetides, Gene Sonic hedgehog (shh), Gene Indian hedgehog (lhh) and Gene Desert hedgehog (Dhh), together with any progeny, mutants or derivatives, to the extent that they contain a substantial portion of the original Biological Materials. Proprietary materials shall mean materials which are not generally available from another source and which are under the control of Licensor.

Sonic hedgehog is a protein that in humans is encoded by the SHH ('sonic hedgehog') gene. Both the gene and the protein may also be found notated alternatively as 'Shh'.Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain.

Milestone Products shall mean products which are not Licensed Products and are identified or discovered in material part through the use of processes or subject matter covered in a Claim or agonize or antagonize members of the hedgehog gene family or agonize or antagonize follistatin or incorporate a substantial portion of a Biological Material or which could not be made except by utilizing a Biological Material or are antibodies which bind to a hedgehog protein.

PATENT RIGHTS shall mean United States patent application Serial No. 08/136.748 filed October 14. 1993 and United States patent application Serial No. 08/176.427 filed December 30. 1993. United States Patent Application Serial No. 09/394.020. filed September 10,1999.

Field of Use
The Licensee is a therapeutic drug development company principally focused on the discovery, development and future commercialization of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs.

IPSCIO Record ID: 299283

License Grant
Licensor of Canada grants an exclusive license under Licensors patent rights to make, have made, use, and sell Licensed Products and to practice the Licensed methods throughout the world where Licensor may lawfully grant such a license.

Licensor also grants to the right to issue sublicenses.

License Property
Licensor has certain genetic research for the isolation, sequencing, and identification of cancer genes

Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.

Licensed technology also includes
—  the human BRCA2 gene(s);
—  any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
—  any BRCA2 protein molecules;
—  nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
—  any mutations or altered form of the BRCA2 gene(s);
—  any animal or human homologues of the BRCA2 gene(s);
—  any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

Licensed technology further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications.

Field of Use
The field of use is for the commercial development, use and sale of any inventions that may result from the discovery of the BRCA2 breast cancer gene.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.